Get started
Genetic Technologies Ltd.Genetic Technologies Ltd.Genetic Technologies Ltd.

Genetic Technologies Ltd.

No trades
See on Supercharts
Overview Financials News
Ideas
Technicals

GNTLF trade ideas

Genetic Technologies USA Sun Storm Investment Trading Desk & NexGen Wealth Management Service Present's: SSITD & NexGen Portfolio of the Week Series Focus: Worldwide By Sun Storm Investment Research & NexGen Wealth Management Service A Profit & Solutions Strategy & Research Trading | Investment | Stocks | ETF | Mutual Funds | Crypto | Bonds | Options | Dividend | Futures | USA | Canada | UK | Germany | France | Italy | Rest of Europe | Mexico | India Disclaimer: Sun Storm Investment and NexGen are not registered financial advisors, so please do your own research before trading & investing anything. This is information is for only research purposes not for actual trading & investing decision. #debadipb #profitsolutions
NASDAQ:GENE
by Sunstorminvest
GENE: Last Breakout was Crazy, High Volume Pop?GENE is one of those stocks that had support pickup for volume which lead to a really big breakout. The selloff was as bad, given many people getting excited can leave just as quick. I'm not sure I would consider it far enough evidence yet for market manipulation. That being said, even with lots of the resistance it has been receiving, I think it has potential for a positive retest. I would rate this as mid risk, but think that bullish correlations can push this past the $7 price point quite soon. That being said, please do your own due diligence. Invest at your own risk. Everything I say is on an opinion based basis.
NASDAQ:GENELong
by gamer456148
1
Update on COVID-19 Disease Severity TestGenetic Technologies Provides Update on COVID-19 Disease Severity Test Highlights -Genetic Technologies has filed a provisional patent for its COVID-19 Severity Risk Test with the Patent Office in Australia -The COVID-19 Severity Risk Test comprises a polygenic risk test (PRS) and assessment for clinical risk factors -Genetic Technologies has completed the design and request for initial production of the SNP (Single Nucleotide Polymorphism) panel required to process the polygenic risk test portion of the COVID-19 Severity Risk Test from US-based Thermo Fisher Scientific -Genetic Technologies has confirmed with major manufacturers that the COVID-19 Severity Risk Test, including a reagent and SNP panel, is capable of being rolled out on a large scale -Discussions held with Centres for Medicare and Medicaid Services (CMS) and National Association of testing Authorities, Australia (“NATA”) for regulatory Approval for the COVID-19 Severity Risk Test in the United States and Australia Genetic Technologies has filed a provisional patent for its COVID-19 Severity Risk Test with IP Australia (2020901739 – Methods of assessing risk developing a severe response to Coronavirus infection) www.globenewswire.com Furthermore, the company has confirmed capacity to scale up production for a global-roll out of the COVID-19 test (reagent and SNP panel) with major manufacturers. The Company's Australian facilities will have the capacity of producing up to 250,000 tests per year. The scale-up of manufacturing will require global distribution partnerships if COVID-19 Severity Risk Test is widely adopted. GENE is in discussion with the respective regulatory authorities for approval of COVID-19 Severity Risk Test in the U.S. and Australia. seekingalpha.com
NASDAQ:GENE
by AlenCiken